-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News April 25, 2021 // --PAPR inhibitors (PARPi) have proven their anti-tumor efficacy in breast cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, although PARPi monotherapy is not effective It treats patients with metastatic triple-negative breast cancer (TNBC) carrying wild-type BRCA1/2, but the researchers speculate that PARPi may be effective for patients with primary TNBCs who have not previously received chemotherapy
Annals of Oncology Olaparib monotherapy may be expected as the main treatment for non-selective triple-negative breast cancer patients; and targeted therapy for early-stage breast cancer may provide help to significantly increase the success rate of treatment
Image source: https:// (Poly ADP-ribose polymerase) inhibitor is a targeted therapy suitable for many types of cancer, including prostate cancer, ovarian cancer and rare breast cancer
PARP (Poly ADP-ribose polymerase) inhibitor is a targeted therapy suitable for many types of cancer, including prostate cancer, ovarian cancer and rare breast cancer
The researchers said that of the 32 patients treated, 18 (56%) patients were effective on olaparib monotherapy, which was manifested as tumor regression; most importantly, 16 of the 18 responders All of them showed special molecular markers (gene mutations or so-called epigenetic modifications), which may help predict the benefits of genes involved in the DNA repair process, and only 4 of the 14 non-responders were Such a situation
Of the 32 patients who received treatment, 18 (56%) patients were effective on olaparib monotherapy, which was manifested by regression of tumors; most importantly, 16 of the 18 responders showed signs of Special molecular markers (gene mutations or so-called epigenetic modifications) may help predict the benefits of genes involved in the DNA repair process, which is the case for only 4 of the 14 non-responders
Summary of the research group of the PETREMAC new auxiliary trial
Image source: HP Eikesdal, et al.
Annals of Oncology
However, among patients who did not carry this germline mutation (ie, patients who would normally be excluded from PARP inhibitor treatment), 54% (14/26) of the patients responded to the treatment.
The researchers believe that the results of this study challenge the previous dogmatic view that PARP inhibition may not have an effect on cancer patients who do not carry germline mutations.
OncoPrint list of homologous recombination gene mutations in triple-negative breast cancer patients (N=32) from the PETREMAC clinical trial
Image source: HP Eikesdal, et al.
Annals of Oncology
In summary, in addition to germline homologous recombination mutations, olaparib therapy can produce a higher clinical response rate in the treatment of triple-negative breast cancer with homologous recombination defects
Although previous studies have found that PAPR inhibition has no therapeutic benefit for advanced breast cancer, the results of this article have found that therapies that have no therapeutic benefit in the treatment of advanced breast cancer may potentially treat early-stage breast cancer
Original source:
HP Eikesdal, S.
HP Eikesdal, S.
Yndestad, A.
Elzawahry, et al.
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer , Annals of Oncology (2020).
DOI:10.
1016/j.
annonc.
2020.
11.
009 Olaparib monotherapy as primary treatment in unselected triple negative breast cancer Annals of Oncology
